Chronic Administration of Mood Stabilizers Upregulates BDNF and Bcl-2 Expression Levels in Rat Frontal Cortex
- 314 Downloads
Brain-derived neurotrophic factor (BDNF) and B-cell lymphoma-2 (Bcl-2) proteins are neuroprotective factors involved in neuronal signaling, survival and plasticity. Both can be regulated by cyclic AMP response element binding (CREB) protein. Decreased levels of BDNF and Bcl-2 are implicated in the pathogenesis of bipolar disorder. The present study investigated whether chronically administered mood stabilizers would increase BDNF and/or Bcl-2 levels in rat brain. Real time RT-PCR, sandwich ELISA and Western blotting were used to measure BDNF and Bcl-2 mRNA and protein levels in the frontal cortex of rats chronically administered carbamazepine (CBZ) or lamotrigine (LTG) to produce plasma concentrations therapeutically relevant to bipolar disorder. Chronic CBZ and LTG significantly increased BDNF and Bcl-2 mRNA and protein levels in the frontal cortex. A common mechanism of action of mood stabilizers in the treatment of bipolar disorder may involve neuroprotection mediated by upregulation of brain BDNF and Bcl-2 expression.
KeywordsBDNF Bcl-2 Lithium Valproate Carbamazepine Lamotrigine Brain Bipolar Disorder Rat
Brain derived neurotrophic factor
cAMP response element binding protein
This work was entirely supported by the Intramural Research Program of the National Institute on Aging, National Institutes of Health. We thank the National Cancer Institute (NCI), Center for Cancer Research (CCR) Fellows Editorial Board, for proofreading the manuscript.
- 25.Yasuda S, Liang MH, Marinova Z, Yahyavi A, Chuang DM (2007) The mood stabilizers lithium and valproate selectively activate the promoter IV of brain-derived neurotrophic factor in neurons. Mol Psychiatry (in press)Google Scholar
- 30.Okada T, Hashimoto R, Numakawa T, Iijima Y, Kosuga A, Tatsumi M et al (2006) A complex polymorphic region in the brain-derived neurotrophic factor (BDNF) gene confers susceptibility to bipolar disorder and affects transcriptional activity. Mol Psychiatry 11:695–703. doi: 10.1038/sj.mp.4001822 PubMedCrossRefGoogle Scholar
- 31.Rybakowski JK, Borkowska A, Skibinska M, Szczepankiewicz A, Kapelski P, Leszczynska-Rodziewicz A et al (2006) Prefrontal cognition in schizophrenia and bipolar illness in relation to Val66Met polymorphism of the brain-derived neurotrophic factor gene. Psychiatry Clin Neurosci 60:70–76. doi: 10.1111/j.1440-1819.2006.01462.x PubMedCrossRefGoogle Scholar
- 43.Lyons WE, Mamounas LA, Ricaurte GA, Coppola V, Reid SW, Bora SH et al (1999) Brain-derived neurotrophic factor-deficient mice develop aggressiveness and hyperphagia in conjunction with brain serotonergic abnormalities. Proc Natl Acad Sci USA 96:15239–15244. doi: 10.1073/pnas.96.26.15239 PubMedCrossRefGoogle Scholar